Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis after the FDA’s feedback for a clearer path.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results